<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03053544</url>
  </required_header>
  <id_info>
    <org_study_id>472-2015</org_study_id>
    <nct_id>NCT03053544</nct_id>
  </id_info>
  <brief_title>Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer</brief_title>
  <official_title>Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer: An Internal Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunnybrook Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase II, single arm, controlled, open label internal pilot.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This internal pilot will be the first prospective study to assess the feasibility and&#xD;
      efficacy of adding metformin in non-diabetic rectal patients who undergo standard of care&#xD;
      neoadjuvant chemoradiation therapy (CRT). The translational aim of the study will inform on&#xD;
      predictive factors (such as p53) and mechanism of action (hypoxia, proliferation). Metformin&#xD;
      has been used for decades in patients with type 2 diabetes and has an extremely safe toxicity&#xD;
      profile. With current interest in the use of metformin as a cancer therapeutic in&#xD;
      non-diabetics, this study is expected to provide proof-of principle data for a larger study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 8, 2016</start_date>
  <completion_date type="Actual">June 26, 2019</completion_date>
  <primary_completion_date type="Actual">June 26, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological Complete Response (pCR) rate</measure>
    <time_frame>1 year</time_frame>
    <description>The primary outcome is to evaluate the use of metformin to improve pathological complete response (pCR) rates in non-diabetic participants undergoing standard of care neoadjuvant CRT for rectal cancer.&#xD;
The primary outcome will be measured by the pathological complete response rate after completion of the study treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Proliferation Reduction</measure>
    <time_frame>1 year</time_frame>
    <description>The secondary outcome is to determine if metformin reduces tumor proliferation in this study population. The secondary outcome will be determined by examining tumor cell proliferation from longitudinal biopsy specimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Hypoxia</measure>
    <time_frame>1 year</time_frame>
    <description>The secondary outcome is to determine if metformin reduces tumor hypoxia in this study population. The secondary outcome will be determined by examining tumor cell hypoxia from longitudinal biopsy specimens.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Rectal Neoplasm Carcinoma in Situ Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will self-administer 500mg metformin twice daily by mouth: 1) beginning 1 to 2 weeks prior to standard of care CRT, 2) during standard of care CRT and 3) until 30 days after the end of standard of care CRT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Participants will self-administer 500mg metformin twice daily by mouth: 1) beginning 1-2 weeks prior to standard of care CRT, 2) during standard of care CRT and 3) until 30 days after the end of standard of care CRT.</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Plan for care inclusive of:&#xD;
&#xD;
             i. standard of care neoadjuvant chemoradiation ii. planned total mesorectal excision&#xD;
             (TME)&#xD;
&#xD;
          2. Histologically confirmed adenocarcinoma of the rectum&#xD;
&#xD;
          3. At least one of the following:&#xD;
&#xD;
             i. T3 or T4 lesions ii. T2 lesions â‰¤ 1 mm to the mesorectal fascia iii. Node positive&#xD;
             rectal tumor&#xD;
&#xD;
          4. ECOG performance status of 0 or 1&#xD;
&#xD;
          5. Provide written informed consent&#xD;
&#xD;
          6. Female participants of childbearing potential agree to use adequate methods of&#xD;
             contraception from the start of metformin administration until the start of CRT.&#xD;
             Contraception will not be required to be continued during or after CRT as this&#xD;
             treatment renders participants infertile. Clinically acceptable methods of birth&#xD;
             control for this study include intrauterine devices (IUD), birth control pills,&#xD;
             hormonal implants, injectable contraceptives, and using barrier methods such as&#xD;
             condoms, vaginal diaphragm with spermicide, or sponge.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of diabetes&#xD;
&#xD;
          2. Current use of metformin&#xD;
&#xD;
          3. Prior pelvic radiation&#xD;
&#xD;
          4. Life expectancy &lt; 6 months.&#xD;
&#xD;
          5. Active infection&#xD;
&#xD;
          6. Creatinine &gt; 1.5X ULN, within 1 month prior to baseline&#xD;
&#xD;
          7. AST, ALT &gt; 2.5X ULN, within 1 month prior to baseline&#xD;
&#xD;
          8. Bilirubin &gt; 1.5 ULN, within 1 month prior to baseline&#xD;
&#xD;
          9. Pregnant or breastfeeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shun Wong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marianne Koritzinsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Princess Margaret Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Odette Cancer Centre, Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>December 20, 2016</study_first_submitted>
  <study_first_submitted_qc>February 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2017</study_first_posted>
  <last_update_submitted>September 25, 2019</last_update_submitted>
  <last_update_submitted_qc>September 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>node positive rectal tumors</keyword>
  <keyword>metformin</keyword>
  <keyword>neoadjuvant chemoradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Adenocarcinoma in Situ</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Results from this internal pilot will be disseminated to participants and stakeholders by means of publication and presentation where appropriate.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

